126 related articles for article (PubMed ID: 38661032)
21. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Olson CM; Jiang B; Erb MA; Liang Y; Doctor ZM; Zhang Z; Zhang T; Kwiatkowski N; Boukhali M; Green JL; Haas W; Nomanbhoy T; Fischer ES; Young RA; Bradner JE; Winter GE; Gray NS
Nat Chem Biol; 2018 Feb; 14(2):163-170. PubMed ID: 29251720
[TBL] [Abstract][Full Text] [Related]
22. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.
Richters A; Doyle SK; Freeman DB; Lee C; Leifer BS; Jagannathan S; Kabinger F; Koren JV; Struntz NB; Urgiles J; Stagg RA; Curtin BH; Chatterjee D; Mathea S; Mikochik PJ; Hopkins TD; Gao H; Branch JR; Xin H; Westover L; Bignan GC; Rupnow BA; Karlin KL; Olson CM; Westbrook TF; Vacca J; Wilfong CM; Trotter BW; Saffran DC; Bischofberger N; Knapp S; Russo JW; Hickson I; Bischoff JR; Gottardis MM; Balk SP; Lin CY; Pop MS; Koehler AN
Cell Chem Biol; 2021 Feb; 28(2):134-147.e14. PubMed ID: 33086052
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Shan B; Zhuo Y; Chin D; Morris CA; Morris GF; Lasky JA
J Biol Chem; 2005 Jan; 280(2):1103-11. PubMed ID: 15528190
[TBL] [Abstract][Full Text] [Related]
26. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
27. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
28. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
29. Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.
Kumari N; Iordanskiy S; Kovalskyy D; Breuer D; Niu X; Lin X; Xu M; Gavrilenko K; Kashanchi F; Dhawan S; Nekhai S
Antimicrob Agents Chemother; 2014 Nov; 58(11):6558-71. PubMed ID: 25155598
[TBL] [Abstract][Full Text] [Related]
30. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
31. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
32. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.
Salerno D; Hasham MG; Marshall R; Garriga J; Tsygankov AY; Graña X
Gene; 2007 Dec; 405(1-2):65-78. PubMed ID: 17949927
[TBL] [Abstract][Full Text] [Related]
33. CDK9 inhibitors reactivate p53 by downregulating iASPP.
Wu J; Liang Y; Tan Y; Tang Y; Song H; Wang Z; Li Y; Lu M
Cell Signal; 2020 Mar; 67():109508. PubMed ID: 31866490
[TBL] [Abstract][Full Text] [Related]
34. Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
He S; Fang X; Xia X; Hou T; Zhang T
Oncol Rep; 2020 Nov; 44(5):1929-1938. PubMed ID: 32901849
[TBL] [Abstract][Full Text] [Related]
35. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
Gordon V; Bhadel S; Wunderlich W; Zhang J; Ficarro SB; Mollah SA; Shabanowitz J; Hunt DF; Xenarios I; Hahn WC; Conaway M; Carey MF; Gioeli D
Mol Endocrinol; 2010 Dec; 24(12):2267-80. PubMed ID: 20980437
[TBL] [Abstract][Full Text] [Related]
36. Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae.
Matrone G; Mullins JJ; Tucker CS; Denvir MA
Cell Cycle; 2016 Nov; 15(22):3060-3069. PubMed ID: 27715402
[TBL] [Abstract][Full Text] [Related]
37. CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys.
Yang X; Luo W; Li L; Hu X; Xu M; Wang Y; Feng J; Qian J; Guan X; Zhao Y; Liang G
Toxicol Appl Pharmacol; 2021 Apr; 416():115465. PubMed ID: 33631230
[TBL] [Abstract][Full Text] [Related]
38. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
[TBL] [Abstract][Full Text] [Related]
39. RSV Reprograms the CDK9•BRD4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling.
Brasier AR
Viruses; 2020 Apr; 12(4):. PubMed ID: 32331282
[TBL] [Abstract][Full Text] [Related]
40. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
